Similarly, Krishnan et al. demonstrated that inhibition of Ezrin through expression of a non-phosphorylatable mutant results in reduction of phosphorylation of the serine/threonine kinase AKT at serine 473.40 Since then, we hypothesised that the influence of Ezrin in BC at least in part via the AKT pathway. Here, EZR is linked to breast cancer.